Ginkgo Bioworks Holdings, Inc.
DNAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 9, 2026 | Oppenheimer | $5.00(-28%) | $6.94 | StreetInsider | |
| Aug 25, 2025 | BTIG | $9.00(-25%) | $12.05 | TheFly | |
| Aug 23, 2024 | BTIG | Mark Massaro | $7.00(-16%) | $8.30 | TheFly |
| Nov 29, 2022 | Berenberg Bank | $6.00(+226%) | $1.84 | Benzinga | |
| Aug 16, 2022 | BTIG | $6.00(+60%) | $3.74 | Benzinga | |
| Jun 16, 2022 | Jefferies | $4.35(+68%) | $2.59 | Benzinga | |
| Mar 3, 2022 | Cowen & Co. | Steven Mah | $12.00(+211%) | $3.86 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| TD Cowen | maintain | Hold | Oct 13, 2026 |
| BTIG | maintain | Sell | Sep 4, 2026 |
| TD Cowen | downgrade | Buy →Hold | Aug 7, 2026 |
| BTIG | maintain | Sell | Mar 12, 2026 |
| TD Cowen | maintain | Buy | Jan 8, 2026 |
| BTIG | maintain | Sell | Aug 25, 2025 |
| TD Cowen | maintain | Buy | Sep 20, 2024 |
| BTIG | maintain | Sell | Aug 23, 2024 |
| Goldman Sachs | maintain | Sell | Jul 9, 2024 |
| BTIG | maintain | Sell | Jun 26, 2024 |
| Morgan Stanley | maintain | Equal Weight | May 15, 2024 |
| BTIG | downgrade | Neutral →Sell | May 15, 2024 |
| William Blair | downgrade | Market Perform →Underperform | May 10, 2024 |
| TD Cowen | maintain | Outperform | Mar 1, 2024 |
| Goldman Sachs | maintain | Sell | Jan 23, 2024 |
| Goldman Sachs | maintain | Sell | Jan 22, 2024 |
| Raymond James | downgrade | Outperform →Market Perform | Nov 15, 2023 |
| Raymond James | downgrade | Outperform →Market Perform | Nov 14, 2023 |
| BTIG | downgrade | Buy →Neutral | Nov 9, 2023 |
| Goldman Sachs | maintain | Sell | Jun 5, 2023 |
| Goldman Sachs | downgrade | Neutral →Sell | Jun 2, 2023 |
| William Blair | downgrade | Outperform →Market Perform | May 11, 2023 |
| Berenberg | maintain | Buy | Nov 29, 2022 |
| Morgan Stanley | maintain | Equal Weight | Oct 4, 2022 |
| BTIG | maintain | Buy | Aug 16, 2022 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-1.04| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.64 | $-0.68 | $27.7M | $21.5M |
| Aug 5, 2026 | $-0.75 | $-0.90 | $20.2M | $24.1M |
| May 7, 2026 | $-1.39 | $-1.21 | $19.5M | $42.9M |
| Feb 26, 2026 | $-1.42 | $-1.80 | $33.0M | $37.1M |
| Nov 6, 2025 | $-1.45 | $-1.24 | $38.8M | $38.9M |
| Aug 7, 2025 | $-1.10 | $-1.44 | $49.6M | $41.6M |
| May 6, 2025 | $-1.68 | $-1.23 | $48.3M | $38.8M |
| Feb 25, 2025 | $-1.82 | $-1.45 | $43.8M | $44.5M |
News
Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.
Ginkgo Bioworks NYSE: DNA reported lower third-quarter revenue but narrowed its loss as restructuring-related expense cuts took hold, while executives highlighted new customers for its autonomous laboratory systems and cloud-based lab services.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the third quarter of 2026 that ended September 30, 2026. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. Third Quarter 2026 Financial Results Third quarter 2026 Revenue of $28 million compared to $29 million in the comparable prior year perio.
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Should investors follow Wood's lead with this eVTOL manufacturer?
Hugging Face released a new AI model that allows users to "chat with DNA." Carbon-X can analyze and generate DNA and allows researchers to ask questions in plain language.
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of…
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation's X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
/PRNewswire/ -- Araceli Biosciences und Ginkgo Bioworks (NYSE: DNA) gaben heute die Integration des Endeavor-High-Content-Imaging-Geräts von Araceli in
BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation's X-Labs program. Ginkgo's support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
/PRNewswire/ -- Araceli Biosciences y Ginkgo Bioworks (NYSE: DNA) han dado a conocer hoy la integración del instrumento de imágenes de alto contenido Endeavor
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) reached a new 52-week high on Tuesday. The company traded as high as $18.22 and last traded at $15.5170, with a volume of 2024663 shares. The stock had previously closed at $14.98. Analyst Upgrades and Downgrades Several analysts recently issued reports on DNA shares. Zacks Research
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) saw unusually-strong trading volume on Monday. Approximately 2,686,466 shares changed hands during mid-day trading, an increase of 111% from the previous session's volume of 1,273,783 shares. The stock last traded at $14.8780 and had previously closed at $12.35. Wall Street Analysts Forecast Growth DNA has been
Ginkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery. The stock has skyrocketed since the partnership was announced.
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.